



Discussion Question

What are some of the current challenges in conducting trials for the development of novel agents for BCG-unresponsive high-risk papillary Ta/T1 NMIBC?

Audience members, please share your thoughts by typing in chat.

Discussion Question

(Respond in chat)



What is a clinically meaningful treatment effect on recurrence-free survival in papillary high-risk BCG-unresponsive NMIBC?

- IBCG suggested that a recurrence-free rate of 50% at 6 months, 30% at 12 months, and 25% at 18 months is recommended.